

PUBLICATIONS

Bhaskar, V., Goldfine, I.D., Gerstner, R., Michelson, K., Tran, C., Nonet, G., Bohmann, D., Pongo, E., Zhao, J., Horwitz, A.H., Takeuchi, T., White, M.L., Corbin, J.A. (2016) An Allosteric Antibody to the Mouse Leptin Receptor Reverses the Diabetic Phenotype and Markedly Reduces Body Weight in the ob/ob Mouse. *Obesity* 24(8):1687-94.

Corbin, J.A., **Bhaskar, V.**, Goldfine, I.D., Bedinger, D.H., Kuan, H.F., Lau, A., Narasimha, A.J., Gross, L.M., Handa, M., Maddux, B.A., Watson, S.R., Levy, R., Webster, L., Wijesuriya, S., Liu, N., Wu, X., Chemla-Vogel, D., Lee, S.R., Wong, S., Tran, C., White, M.L. (2014) An Allosteric Human Monoclonal Antibody that Enhances Insulin Binding to the Insulin Receptor and Improves Glycemia in Mouse Models of Diabetes and Insulin Resistance. *PLoS One* 9(2):e88684.

Corbin, J.A., **Bhaskar, V.**, Goldfine, I.D., Rubin, P., Narasimha, A.J., Tran, C., Lau, A., Kuan H.F., Maddux, B.A., Bedinger, D.H., Issafras, H., Watson, S.R., Levy, R., Chemla-Vogel, D., Handa, M., Webster, L., Wijesuriya, S., Liu, N., Wu, X., White, M.L. (2014) Inhibition of the Insulin Receptor Function by a Human, Allosteric, Monoclonal Antibody: A Novel Approach for the Treatment of Hyperinsulinemic Hypoglycemia. *mAbs* 6(1), 262-72.

Bhaskar, V., Lau, A., Narasimha, A.J., Gross, L.M., Goldfine, I.D., Wong, S., Cheung, B., White, M.L. Corbin, J.A. (2012) XMetA, an allosteric activator of the insulin receptor, improves glycemic control in diet-induced obesity mice. *Diabetes Obes Metab* 15(3), 272-75.

Bhaskar, V., Goldfine, I.D., Bedinger, D.H., Kuan, H.F., Lau, A., Narasimha, A.J., Gross, L.M., Handa, M., Maddux, B.A., Watson, S.R., Levy, R., Webster, L., Wijesuriya, S., Liu, N., Wu, X., Chemla-Vogel, D., Lee, S.R., Wong, S., Tran, C., White, M.L., Corbin, J.A. (2012) XMetA, an allosteric agonist monoclonal antibody to the insulin receptor, stimulates insulin activity and improves glycemic control. *Diabetes* 61(5), 1263-71.

Bhaskar, V., Yin, J., Phan, D., Vanegas, S., Mirza, A.M., Issafras, H., Michelson, K., Hunter, J.J. and Kantak, S. (2011) XOMA 052, a monoclonal antibody targeting interleukin-1 beta reduces biomarkers of atherosclerosis and inhibits atherosclerotic plaque formation in apolipoprotein E-deficient mice. *Atherosclerosis* 216(2), 313-20.

Ramakrishnan, V., **Bhaskar, V.**, Fox, M., Wilson, K., Cheville, J.C., Finck, B.J. (2009) "Integrin alpha5beta1 as a novel therapeutic target in renal cancer." In *Renal Cancer* (ed Bukowski, Motzer and Figlin), Humana Press.

Sawada, K., Mitra, A.K., Radjabi, A.R., **Bhaskar, V.**, Kistner, E. O., Tretiakova, M., Jagadeeswaran, S., Montag, A., Becker, A., Kenny, H., Peter, M.E., Ramakrishnan, V., Yamada, S. D., Lengyel E. (2008). Loss of E-Cadherin induces ovarian cancer metastasis through alpha5 Integrin, which is an effective therapeutic target. *Cancer Res* 68(7), 2329-39.

Bhaskar, V., Fox, M., Breinberg, D., Wong, M., Wales, P.E., Rhodes, S. DuBridge, R.B., Ramakrishnan, V. (2008). Volociximab, a chimeric integrin alpha5beta1 antibody, inhibits the growth of VX2 tumors in rabbits. *Invest New Drugs* 26(1), 7-12.

Bhaskar, V., Zhang, D., Fox, M., Seto, P., Wong, M., Wales, P.E., Powers, D., Chao, D. T., DuBridge, R.B., Ramakrishnan, V. (2007). A function blocking anti-mouse integrin alpha5beta1 antibody inhibits angiogenesis and impedes tumor growth *in vivo*. *J Trans Med* 5, 61.

Ramakrishnan, V., **Bhaskar, V.**, Debbie Law, D.A., Wong, M., DuBridge, R.B., O'Hara, C., Powers, D., Liu, G., Grove, J., Hevezi, P., Watson, S., Evangelista, F., Powers, R., Finck, B., Wills, M., Caras, I., Fang, Y., McDonald, D., Johnson, D., Murray, R., Jeffry, U. (2006). Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent. *J Exp Ther Oncol* 5(4), 273-86.

Afar, D.E.* , **Bhaskar, V.***, Ibsen, E., Breinberg, D., Henshall, S.M., Kench, J.G., Drobnik, M., Powers, R., Wong, M., Evangelista, F., O'Hara, C., Powers, D., BuBridge, R.B., Caras, I., Winter, R., Anderson, T., Solvason, N., Stricker, P.D., Cordon-Dardo, C., Scher, H.I., Grygiel, J.J., Sutherland, R.L., Ramakrishnan, V., Law, D.A. (2004). Preclinical validation of anti-TMEFF2-auristatin E-conjugated antibodies in the treatment of prostate cancer. *Mol Cancer Ther* 3(8), 921-32.

Smith, M., **Bhaskar, V.**, Fernandez, J., Courey, A.J. (2004). Drosophila Ulp1, a nuclear pore-associated SUMO protease, prevents accumulation of cytoplasmic SUMO conjugates. *J Biol Chem*. 279(42), 43805-14.

Bhaskar, V., Law, D.A., Ibsen, E., Breinberg, D., Cass, K.M., DuBridge, R.B., Evangelista, F., Henshall, S.M., Hevezi, P., Miller, J.C., Pong, M., Powers, R., Senter, P., Stockett, D., Sutherland, R.L., von Freedden-Jeffry, U., Willhite, D., Murray, R., Afar, D.E.H., Ramakrishnan, V. (2003). E-selectin upregulation allows for targeted drug delivery in prostate cancer. *Cancer Res* 63(19), 6387-94.

Bhaskar, V. and Courey, A.J. (2002). The MADF-BESS domain factor Dip3 potentiates synergistic activation by Dorsal and Twist. *Gene* 299(1-2), 173-84.

Bhaskar, V., Smith, M.T., Courey, A.J. (2002). Conjugation of Smt3 (SUMO) to Dorsal may potentiate the *Drosophila* immune response. *Mol Cell Biol* 22(2), 492-504.

Bhaskar, V., Valentine, S.A., Courey, A.J. (2000). A functional interaction between Dorsal and components of the Smt3 (SUMO) conjugation machinery. *J Biol Chem* 275(6), 4033-40.

Jantzen, H-M., Gousset, L., **Bhaskar, V.**, Vincent, D., Tai, A., Reynolds, E.E., Conley, P.B. (1999). Evidence for two distinct G-protein-coupled ADP receptors mediating platelet activation. *Thromb Haemost* 81(1), 111-7.

* Authors contributed equally to this work